French
DeutschBI 224436
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 7 hrs (simulated)[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C27H26N2O4 |
| Molar mass | 442.515 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
BI 224436 was an investigational new drug under development for the treatment of HIV infection. BI 224436 is the first non-catalytic site integrase inhibitor (NCINI). It inhibits HIV replication via binding to a conserved allosteric pocket of the HIV integrase enzyme. This makes the drug distinct in its mechanism of action compared to raltegravir and elvitegravir, which bind at the catalytic site.[2] In October 2011, Gilead Sciences purchased exclusive rights to develop BI 224436 and several related compounds under investigation in Boehringer Ingelheim’s noncatalytic site integrase inhibitor program.[3][4]
Clinical trials were abandoned in advance of Phase 1.[5]
References
[edit]- ^ Brown A, McSharry J, Kulawy R (17 September 2011). Pharmacodynamics of BI 224436 for HIV-1 in an in vitro hollow fiber infection model system. 51st Interscience conference on antimicrobial agents and chemotherapy. Chicago. pp. 17–20.
- ^ Fenwick C, Bethell R, Cordingley M, Edwards P, Quinson AM, Robinson P, Simoneau B, Yoakim C (17 September 2011). Levin J (ed.). BI 224436, a non-catalytic site integrase inhibitor, is a potent inhibitor of the replication of treatment-naïve and raltegravir-resistant clinical isolates of HIV-1. 51st Interscience Conference on Antimicrobials and Chemotherapy. Chicago: ICAAC.
- ^ "Gilead Negotiates Worldwide License to BI's Early Clinical Stage HIV Program". Genetic Engineering and Biotechnology News. 6 October 2011. Archived from the original on 23 January 2013.
- ^ Highleyman L (7 October 2011). "ICAAC: New Integrase Inhibitor BI 224436 Active against Raltegravir-Resistant HIV". HIVandHepatitis.com.
- ^ Clinical trial number NCT01276990 for "Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 in Healthy Male Volunteers." at ClinicalTrials.gov
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |